Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
BLTE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.50 - $86.53
Previous CloseN/A
Volume15.47K
Average Volume (3M)47.29K
Market Cap
$1.82B
Enterprise Value$1.33B
Total Cash (Recent Filing)$6.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
May 07, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding32,281,760
10 Day Avg. Volume50,076
30 Day Avg. Volume47,292
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.33K
Enterprise Value/Ebitda-36.30
Forecast
1Y Price Target
$96.67Price Target Upside76.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Belite Bio, Inc. ADR News
PremiumCompany Announcements
Belite Bio Announces Key Resolutions from 2025 General Meeting
PremiumCompany Announcements
Belite Bio, Inc. Appoints New Auditor
PremiumCompany Announcements
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress
PremiumCompany Announcements
Belite Bio Announces 2025 Annual Shareholder Meeting---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 DRAGON study has shown positive interim results in Stargardt Disease, supporting the analyst's Buy rating.
Regulatory ProgressTinlarebant holds multiple designations, including Fast Track and Orphan Drug, which could facilitate its market entry as the first FDA-approved treatment for STGD1.
Bears Say
Financial PerformanceDespite a market cap of ~$2.5B, there are concerns about whether Belite can sustain its recent strong performance.
---
Ownership Overview
7.30%
Insiders
0.03% Mutual Funds
0.53% Other Institutional Investors
92.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $32.50 and its highest was $86.53 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $1.82B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is May 07, 2025 which is in 14 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Mar 17, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.308 by -$0.012.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.35.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 32,281,760 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.308. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
---
Belite Bio, Inc. ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.67 (76.76% Upside)
$96.67 (76.76% Upside)
Blogger Sentiment
Bullish
BLTE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 781.0 Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.45%
12-Months-Change
Fundamentals
Return on Equity
-30.60%
Trailing 12-Months
Asset Growth
60.74%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
---
BLTE Company Deck
---
BLTE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented both positive and negative aspects. Significant advancements and regulatory designations for Tinlarebant, along with strong clinical trial enrollment and financial stability, were highlighted as major achievements. However, increased expenses, net loss, adverse events in trials, and high dropout rates were notable challenges. Despite the challenges, the overall sentiment was cautiously optimistic due to strong progress in clinical trials and financial stability.Read More>---
BLTE Stock 12 Month Forecast
Average Price Target
$96.67
▲(76.76% Upside)
Technical Analysis
Denali Therapeutics
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Best Analysts Covering BLTE
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+44.86%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +44.86% per trade.
---